NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer (ADAPTHER2-IV)
NeoAdjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Trastuzumab-deruxtecan Versus Pacli-/Docetaxel+Carboplatin+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer
Sponsor: AstraZeneca
Listed as NCT05704829, this PHASE2 trial focuses on HER2-positive Early Breast Cancer and remains ongoing. Sponsored by AstraZeneca, it has been updated 10 times since 2024, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Dec 2025 — Present [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE2
-
Sep 2025 — Nov 2025 [monthly]
Recruiting PHASE2
-
Mar 2025 — Sep 2025 [monthly]
Recruiting PHASE2
-
Dec 2024 — Mar 2025 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 5 earlier versions
-
Sep 2024 — Dec 2024 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
-
May 2023 — Oct 2023 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2023 — May 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- West German Study Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Augsburg, Germany , Baden-Baden, Germany , Berlin, Germany , Bielefeld, Germany , Braunschweig, Germany , Bremerhaven, Germany , Cologne, Germany , Düsseldorf, Germany , Eschweiler, Germany and 25 more locations